secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
CIK:        0001757499
Form:       8-K
Filed at:   2024-09-04T23:59:59+00:00
Accession:  0001493152-24-034987
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shuttle Pharma begins Phase 2 glioblastoma trial; regains Nasdaq compliance
---------------------------------------------------------------------------

- Phase 2 trial of Ropidoxuridine for glioblastoma opened at two sites; four more anticipated this month.
- 40 patients initially randomized to 1,200 mg/day or 960 mg/day; then 14 more on optimal dose.
- FDA Orphan Drug Designation granted for Ropidoxuridine; potential marketing exclusivity.
- Nasdaq non-compliance resolved after filing re-audited financials and delayed Q2 2023 10-Q.
- Trial expected to complete in 18-24 months; primary endpoint survival vs historical controls.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1757499/000149315224034987/0001493152-24-034987-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1757499/000149315224034987/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-034987

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer